Member Info for davidpqz

Terrific results in animal models. Sadly clinical trials take years. I think AVCT is a great short term and long term investment but not so sure of the medium term .

"100% specificity can be achieved but at the expense of sensitivity". It doesn't follow.

Do you know how much you can sell 17,000 barrels of oil for?

Reminds of RENE 18 months ago when the early tests of its retinitis pigmentosa treatment came in. Went from 80p to £3 in days. One to watch, by the way.

Why are the odx guys even on this bb? How does it profit them? Perhaps they're trying to drive the price down so they can join the party. Good luck on that.

and he emphasised that LTF tech is not revolutionary - that it is already in use for other conditions.

Did mention lateral flow in response to a question.

The website has had a make over ! It looks much more attractive !

It's not uncommon in large scale testing and happened before resulting in a delay of a couple of days. People get sick.

A combined test could be very powerful. There is currently an incidence of Covid in the UK population of 0.05% (1 in 2000). We are assured that the specificity of our LFT test is very high. The most pessimistic sensitivity figure for LFT tests that I've seen is 50%. and I think a reasonable interpretation of 'highly specific' is 98%. If you take a test group of 10,000 people these figures produce a set of approx 200 positive results. These could be quarantined and retested using PCR - probably within 48 hours or less.
It's a method of applying coarse and fine filters. The coarse (highly specific) filter enables 9,800 people to go back to work. It will identify 2.5 true positives and miss 2.5 . However being able to exclude 50% of truly infected people from the population could take the R number below the critical value of 1.
I think the CEO has indicated that the sensitivity is much higher than 50% but even at that low level the LFT could be very effective.

WHAT

"The most infectious people"

Bloody hell. They're sounding çonfident

I agree that it is easily fixed. The fact that it hasn't been fixed points to lack luster management. I'm not inspired by the company but the cost savings from the prepack admin are very substantial and they recovered very strongly from exactly the same situation in 2008.

They did another prepack back in 2008/9 after which the business was very successful resulting in the IPO in 2017 . Paul Scott on Stockopedia has written a very insightful piece and rates Quiz as high risk with the a real potential to multibag. Stocko isn't cheap but it has paid for itself every year that I've been a member.
Retail is recovering - a recent report said that is 3% up on last year but the lead is being taken by online retail for as we all know, the high street is suffering badly. For that reason I'm very interested in online retail. My man reservation with Quiz is that if you compare its website with Sosandar it looks a bit amateurish whereas Sosandar is vibrant and eye catching. One example is when you place your cursor on a dress it shows another view . Not rocket science but very useful I imagine when buying a dress. Long term I much prefer Sosandar.
By the way, I'm not interested in BooHoo as it is already on an astronomical valuation.

BWNG 12 mo forecast p/e 4.9
BOO 12 mo forecast p/e 35.9

TGoodland has a point. Instead of knee jerk denial and insult, perhaps it could be discussed? This is what makes these BB's useless.

Her second point seems to be that only big pharma have the infrastructure to get a newly approved drug to market and SNG is too small to do it on their own. Perhaps she hadn't read this on SNG's website :
"Since the outbreak of COVID-19, Synairgen has been approached by, and is in discussion with, a number of other medical, scientific, and Governmental bodies (both in the UK, US and internationally) seeking to investigate novel therapeutics in this area."

Synairgen's treatment replaces a deficiency in a protein (Interferon beta) which is already produced by the lungs in response to the virus. Injectable interferon beta is already approved as a medicine and is in use. This leads me to believe that we have a head start in the race to approvals.
The central point of the MF article is that Phase 3 trials can take a very long time. The company has said that they intend to develop SNG001 as rapidly as possible and I tend to believe them.

Distribution agreements are not sales. I am minded of Fox Marble which periodically publishes memorandums of understanding generating a flurry of interest but has been in steady decline for years.
No one has produced a reason for today's spectacular rise. Someone mentioned anti viral properties but gave no reference and I have found none. All I can think of is the listing in the US where a lot of free money is looking for a home. Of course there may be news later today that graphene is the cure for cancer but right now I don't see it. Enjoy your profits !